Phillips Wealth Planners LLC Purchases 808 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Phillips Wealth Planners LLC grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 10.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,733 shares of the biopharmaceutical company’s stock after acquiring an additional 808 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Royalty Pharma were worth $246,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. First Trust Direct Indexing L.P. increased its stake in Royalty Pharma by 41.1% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 26,847 shares of the biopharmaceutical company’s stock valued at $760,000 after purchasing an additional 7,817 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Royalty Pharma by 62.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 86,190 shares of the biopharmaceutical company’s stock valued at $2,438,000 after buying an additional 33,206 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Royalty Pharma by 2.4% during the third quarter. DekaBank Deutsche Girozentrale now owns 746,287 shares of the biopharmaceutical company’s stock worth $20,836,000 after acquiring an additional 17,159 shares in the last quarter. Forsta AP Fonden raised its holdings in shares of Royalty Pharma by 2.8% in the 3rd quarter. Forsta AP Fonden now owns 242,400 shares of the biopharmaceutical company’s stock worth $6,857,000 after acquiring an additional 6,500 shares during the last quarter. Finally, Lake Street Advisors Group LLC bought a new position in Royalty Pharma in the 3rd quarter valued at about $211,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $27.10 on Friday. The firm has a market capitalization of $16.08 billion, a P/E ratio of 23.98, a price-to-earnings-growth ratio of 4.00 and a beta of 0.46. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. The business’s fifty day simple moving average is $27.97 and its 200 day simple moving average is $27.57. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. During the same period in the previous year, the firm earned $0.85 EPS. As a group, analysts anticipate that Royalty Pharma plc will post 4.05 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s dividend payout ratio is currently 74.34%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RPRX shares. StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a report on Monday, October 28th. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. Morgan Stanley raised their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Finally, The Goldman Sachs Group upped their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.